Journal of Structural Biology 2012-10-01

Identification and structural characterization of two 14-3-3 binding sites in the human peptidylarginine deiminase type VI.

Rolf Rose, Micheline Rose, Christian Ottmann

Index: J. Struct. Biol. 180(1) , 65-72, (2012)

Full Text: HTML

Abstract

The regulation and function of peptidylarginine deiminase isoform VI (PAD6), which is a highly abundant protein associated with the cytoplasmic lattices in mammalian oocytes, is poorly understood so far. It has been shown previously, that 14-3-3 proteins, a class of regulatory adapter proteins ubiquitous in eukaryotes, bind to PAD6 in vivo in a phosphorylation dependent manner. Here we identify possible 14-3-3 binding sites in human PAD6 by in silico methods, looking for conserved, surface exposed serine residues. Two of these sites were confirmed as 14-3-3 binding sites by fluorescence polarization competition and X-ray crystallography. We furthermore suggest a role of RSK-type kinases in the phosphorylation of one of these two binding sites and provide evidence in the form of in vitro kinase assays with p70S6 kinase and RSK1.Copyright © 2012 Elsevier Inc. All rights reserved.


Related Compounds

Related Articles:

Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis.

2011-01-01

[Pediatr. Rheumatol. Online J. 9 , 8, (2011)]

The human peptidylarginine deiminases type 2 and type 4 have distinct substrate specificities

2014-04-01

[Biochim. Biophys. Acta 1844(4) , 829-36, (2014)]

Retinal deimination and PAD2 levels in retinas from donors with age-related macular degeneration (AMD)

2013-06-01

[Exp. Eye Res. 111 , 71-8, (2013)]

VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice.

2014-01-02

[Blood 123(1) , 141-8, (2014)]

Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis.

2013-10-01

[Biochim. Biophys. Acta 1829(10) , 1126-35, (2013)]

More Articles...